A new study claims that the Johnson & Johnson (J&J) vaccine for COVID-19, which offers one shot only, may not be as effective against the Delta variant as the other brands.
The report published on July 19 on the medical journal website BioRxiv compared the antibody levels provided by the one-time J&J or Janssen jab with the two-doses Pfizer and Moderna vaccines. It said that the single-shot offered much less protection, especially against the highly contagious Delta version of the Chinese Communist Party (CCP) Virus or COVID-19.
When gauging the effectiveness of the doses in preventing moderate to severe disease, the J&J vaccine only provides 66.9% efficacy, whereas the two-dose vaccines demonstrated 94 to 95% efficiency.
Then as they moved to assess the three types of vaccines’ performance with the Delta and Lambda variants, they said the J&J’s effectiveness in neutralizing the disease was “significantly decreased.”
Speaking of the results, the authors of the research said their findings do not intend to ward people off the doses, but rather, they would recommend additional injection for better protection against the CCP Virus.
“The message that we wanted to give was not that people shouldn’t get the J&J vaccine, but we hope that in the future, it will be boosted with either another dose of J&J or a boost with Pfizer or Moderna,” said virologist Nathaniel Landau who led the study, according to the New York Times.
As the New York Times added, the findings are in line with previous studies of the one-dose AstraZeneca vaccine’s potency against the Delta strain, which indicated a 33% efficacy rate. The one-dose vaccine by AstraZeneca employs the same technology as the J&J version.
This research also produces inconsistent data to the smaller studies by the J&J company, suggesting that the vaccine was effective against Delta and other new variants. However, the outlet additionally provided that the results are based on laboratory tests with blood samples and may not reflect the vaccine’s abilities in real-life application.
It has not been peer-reviewed.
There have not been very positive views about the J&J vaccines. Aside from the occurrence of blood clots as potential side effects, the FDA last week warned that it could lead to a rare neurological disorder.
Currently, the Delta variant makes up 83% of infections in the United States, director of the Centers for Disease Control and Prevention (CDC), Dr. Rochelle Walensky, noted on Tuesday. She suspected that it could cause the recent spike in CCP Virus infections across all 50 states in the country.
While experts believe that Delta may trigger more breakthrough infections than earlier strains of the virus, a vast majority of hospitalizations and fatalities, however, occur among unvaccinated people (99%).
Pfizer is recommending a booster dose for optimum protection against the CCP Virus, saying that the effectiveness of their shots may fade out six months after the inoculation. However, U.S. health agencies and experts have declined the call, given that they needed more scientific data before backing the idea.